2-Aminotetralin derivatives for the therapy of glaucoma

Details 2-Aminotetralin derivatives for the therapy of glaucoma 2-Aminotetralin derivatives for the therapy of glaucoma

2005-10-11

2005-10-11

Killos, Paul J. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C560S139000

Reexamination Certificate

active

06953813

ABSTRACT:
The use of racemic or optically active compounds represented by formula (I) and the salts thereof wherein R is H or CH3for the preparation of pharmaceutical compositions for the therapy of ophthalmic disorders.

REFERENCES:
patent: 5314916 (1994-05-01), York et al.
patent: 6013678 (2000-01-01), Chiesi et al.
patent: 6103760 (2000-08-01), Chiesi et al.
patent: 0 009 702 (1980-04-01), None
patent: 2 123 410 (1984-02-01), None
patent: 2123410 (1984-02-01), None
patent: 96 29065 (1996-09-01), None
patent: 96/29065 (1996-09-01), None
Carmine Morisco et al.: “Hemodynamic effects of graded oral doses of a new dopaminergic analogue CHF 1035 in patients with congestive heart failure” Journal of the American College of Cardiology, no. Spec. Issue, p. 128A 1995.

Affiliated with

Also associated with

Rating

2-Aminotetralin derivatives for the therapy of glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-Aminotetralin derivatives for the therapy of glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-Aminotetralin derivatives for the therapy of glaucoma will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3475589